Takeda Pharmaceutical (NYSE:TAK) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a hold rating to a strong-buy rating in a research note released on Saturday.

Other analysts have also recently issued reports about the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Morgan Stanley assumed coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating for the company. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

TAK opened at $17.21 on Friday. The stock has a fifty day moving average price of $15.41 and a 200 day moving average price of $14.81. The company has a current ratio of 1.37, a quick ratio of 0.76 and a debt-to-equity ratio of 0.61. Takeda Pharmaceutical has a 1 year low of $12.99 and a 1 year high of $17.25. The stock has a market cap of $54.76 billion, a price-to-earnings ratio of 71.71 and a beta of 0.03.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, January 29th. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). The firm had revenue of $7.76 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.73% and a net margin of 2.58%. Analysts forecast that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Institutional investors have recently made changes to their positions in the business. Private Trust Co. NA boosted its stake in Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the period. Twin Peaks Wealth Advisors LLC bought a new stake in shares of Takeda Pharmaceutical in the second quarter valued at approximately $28,000. Evelyn Partners Investment Management LLP boosted its position in shares of Takeda Pharmaceutical by 163.4% in the second quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock valued at $39,000 after acquiring an additional 1,560 shares during the period. True Wealth Design LLC grew its stake in shares of Takeda Pharmaceutical by 1,262.3% in the third quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock worth $40,000 after acquiring an additional 2,512 shares during the last quarter. Finally, NewSquare Capital LLC increased its position in Takeda Pharmaceutical by 182.4% during the second quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock worth $53,000 after acquiring an additional 2,229 shares during the period. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical News Summary

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Takeda raised FY?2025 revenue guidance to $29.4 billion and issued EPS guidance of 3.160, above consensus revenue expectations — a clear near?term positive for top?line visibility and investor sentiment.
• Positive Sentiment: Q3 results beat expectations: EPS $0.95 vs. $0.55 consensus; management cited cost discipline, FX tailwinds and narrowing gap between Growth & Launch products and VYVANSE generic erosion—management is tightening OPEX and raising confidence in the full?year outlook. Takeda Reports Third-Quarter FY2025 Results
• Neutral Sentiment: CEO Christophe Weber discussed succession planning and avoiding a ‘lame duck’ exit — governance and leadership continuity themes that reduce execution risk but are longer?term in impact. Takeda’s Christophe Weber on avoiding a ‘lame duck’ succession
• Neutral Sentiment: Earnings?call and transcript detail product performance, launch timing and cost actions — useful for modeling but not an immediate catalyst. Takeda Q3 FY2025 Earnings Call Transcript
• Negative Sentiment: Analyst downgrade from Buy to Hold after TAK hit 52?week highs — valuation noted as less compelling and the lack of a clear Entyvio successor reduces near?term upside; this can pressure sentiment and limit multiple expansion. Takeda Tests New Highs, But Struggles To Find Entyvio Successor
• Negative Sentiment: Legal exposure: an adverse jury outcome in an Actos-related case and active litigation motions (including efforts to move a Louisiana suit) represent potential liabilities and headline risk that can weigh on the stock. Takeda and Eli Lilly fall foul of jury in Actos Pharma company wants La. suit over stomach acid meds moved

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.